Skip to Content
Merck
CN

SML3592

GSK3179106

≥98% (HPLC)

Synonym(s):

2-(4-(4-ethoxy-6-oxo-1,6-dihydropyridin-3-yl)-2-fluorophenyl)-N-(5-(1,1,1-trifluoro-2-methylpropan-2-yl)isoxazol-3-yl)acetamide

Sign In to View Organizational & Contract Pricing.

Select a Size

About This Item

Empirical Formula (Hill Notation):
C22H21F4N3O4
CAS Number:
1627856-64-7
Molecular Weight:
467.41
UNSPSC Code:
12352200
NACRES:
NA.21

Key Documents

View All Documentation
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

SMILES string

FC(F)(F)C(C)(C)c1[o]nc(c1)NC(=O)Cc2c(cc(cc2)c3c[nH][c](cc3OCC)=O)F

InChI key

IDXKJSSOUXWLDB-UHFFFAOYSA-N

InChI

1S/C22H21F4N3O4/c1-4-32-16-9-19(30)27-11-14(16)12-5-6-13(15(23)7-12)8-20(31)28-18-10-17(33-29-18)21(2,3)22(24,25)26/h5-7,9-11H,4,8H2,1-3H3,(H,27,30)(H,28,29,31)

assay

≥98% (HPLC)

form

powder

storage condition

desiccated

color

white to beige

solubility

DMSO: 2 mg/mL, clear

storage temp.

2-8°C

Quality Level

100

Related Categories

Biochem/physiol Actions

GSK3179106 is a potent and selective gut-restricted RET (Rearranged during transfection) kinase inhibitor. GSK3179106 attenuates abdominal contractions induced by colorectal distention in rat models.
Potent and selective gut-restricted RET (Rearranged during transfection) kinase inhibitor

Storage Class

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Regulatory Information

新产品
This item has

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
0000225833
0000225832
0000216326
0000225833
0000216326

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Exploring the Potential of RET Kinase Inhibition for Irritable Bowel Syndrome: A Preclinical Investigation in Rodent Models of Colonic Hypersensitivity
Journal of Pharmacology and Experimental Therapeutics, 368, 299-307 (2019)
Discovery of a First-in-Class Gut-Restricted RET Kinase Inhibitor as a Clinical Candidate for the Treatment of IBS
ACS Medicinal Chemistry Letters, 9, 623-628 (2018)

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service